Calcium Alpha-Ketoglutarate for Health & Longevity - Quick Reference Sheet

Calcium Alpha-Ketoglutarate for Health & Longevity

Created on 07/17/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A stabilized form of a molecule the body makes naturally that supports cellular energy and gene regulation, both of which decline with age. Animal evidence is far stronger than human evidence, and its central longevity promise stays unproven. A low-cost, biologically plausible option; the main practical concerns are mild digestive upset and an added calcium load. (Full Review)

Protocol

Dose
~1 g/day
Calcium AKG; plain AKG ~1–3 g/day
Form
Delayed/sustained-release
Calcium AKG matches the studied product
Frequency
Single daily dose
With food improves tolerability; splitting reduces GI upset
Time to effect
Biological-aging markers
Months
Human report averaged ~7 months
Felt effects
None expected
No day-to-day subjective effect

Benefits

Contraindications
  • IDH-mutant cancer
  • Hypercalcemia, primary hyperparathyroidism, or sarcoidosis
  • Recurrent calcium kidney stones
  • Advanced chronic kidney disease (eGFR <30)
  • Pregnancy or breastfeeding
Key Interactions
  • Calcium-binding oral drugs (levothyroxine, tetracycline/fluoroquinolone antibiotics, bisphosphonates, oral iron)
  • Thiazide diuretics (hydrochlorothiazide, chlorthalidone)
  • Other calcium and vitamin D supplements
  • mTOR-inhibiting or dietary-restriction-mimicking interventions (rapamycin, metformin, fasting)
  • Digoxin

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal discomfort; excess calcium intake
  • Speculative: Kidney stones and vascular calcification; theoretical tumor metabolism in IDH-mutant cancers; unknown long-term effects of chronic nutrient-sensing suppression

Monitoring

Marker Target Why
Serum calcium 8.6–10.0 mg/dL Detects hypercalcemia from the added calcium load
eGFR >90 mL/min/1.73m² Flags reduced calcium clearance and kidney-stone risk
hs-CRP <1.0 mg/L Tracks the proposed anti-inflammatory benefit
25-Hydroxy Vitamin D 40–60 ng/mL High vitamin D raises calcium absorption, compounding the calcium load
Epigenetic age At or below chronological age The primary marker the intervention targets

Cadence: Serum calcium and kidney function at ~3 months, then every 6–12 months; epigenetic clock and inflammatory markers every 6–12 months

Qualitative Assessment

  • Energy and perceived recovery from exertion
  • General sense of wellbeing
  • Absence of new digestive discomfort as a tolerability check